Drug Trial Radar · NCT05156827
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of TB006 in Participants With Acute Ischemic Stroke
Last checked: Nov 19, 2026Latest source record: Jan 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Jul 26, 2022
Primary completion
Dec 18, 2023
Study completion Dec 18, 2023
Sponsor
- Lead sponsor
- TrueBinding, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multi-center, randomized, parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and safety of TB006 in participants with an Acute Ischemic Stroke (AIS) event with 57 days of treatment.
Conditions
- Acute Ischemic Stroke
Interventions
TB006Drug
TB006 diluted in normal saline, administered through IV infusion over an hour
PlaceboDrug
Normal saline administered through IV infusion over an hour
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with Recovery Success Measured by modified Rankin Scale (mRS) score of 0-1 on the final mRS assessment.Time frame: Day 90
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.